With its front-line treatment of AML in PH3, plus MDS just finished PH2, its market potential will be much bigger than that of SNSS, but yet its market cap is merely 24% of what SNSS is. pps of CYCC will be tripled very soon, watch out.
It is a second line treatment. SNSS has clearly an advantage.
Read the seeking alpha article on CYCC just came out during mid-day today, you know what I am talking about.